All information is reviewed by Dr. Igor I. Bussel, MD. TB-500 is investigational and banned by WADA/USADA.

Ingredient Profile Evidence Grade: B+

TB-500

Clinical Profile: TB-500 (Thymosin Beta-4 Fragment)

Primary Claim: Direct modulation of actin to drive cellular migration, wound healing, and tissue regeneration.

Clinically observed for its systemic ability to reduce inflammation and promote flexibility in recovering muscle and connective tissues.

Clinical Status Phase II/III Research
Molecular Weight: 4963.5 g/mol
WADA Classification: S2. Prohibited
Primary Pathway: Actin Sequestration
01.

What is TB-500?

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (Tβ4). While Tβ4 is a full-length 43-amino acid peptide, "TB-500" as sold in research markets is often specifically the fragment 17-23 (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-OH), which is hypothesized to carry the primary healing properties of the parent molecule.

TB-500 is utilized by physicians to target systemic recovery. The recovery phase often begins with a higher frequency loading period monitored closely by a clinician, followed by an extended, lower-frequency maintenance timeline to support deep tissue remodeling. Due to its systemic nature, TB-500 requires diligent medical oversight to track inflammatory markers and overall patient health.

Biological Role

In the human body, Tβ4 is released by platelets and various cells at the site of injury. It is critical for the formation of new blood vessels (angiogenesis) and the migration of cells to the wound site.

The "Research" Label

In clinical settings, Tβ4 has been investigated for myocardial infarction repair, dry eye syndrome, and epidermal wound healing. In the athletic community, it is used for tendon, ligament, and muscle repair.

02.

Mechanism of Action

G-Actin Sequestration

TB-500's primary function is as a major G-actin sequestering protein. By binding to actin, it regulates the polymerization and depolymerization of cellular filaments, which is the mechanical engine behind cell migration.

  • Actin Binding: Modulates cellular migration. [PubMed ID: 20536454]

  • Cardioprotection: May preserve cardiac function post-injury. [PubMed ID: 21111625]

  • Anti-inflammatory: Demonstrates systemic reduction of inflammatory cytokines. [PubMed ID: 19934006]

The Wolverine Synergy

"If BPC-157 is the architect that designs the repair, TB-500 is the logistics fleet that moves the materials to the construction site."

01
Dual-Path Angiogenesis

Both peptides promote blood flow, but through different biological triggers, potentially accelerating the healing of 'white zone' tissues (tendons/ligaments).

02
Systemic vs. Localized

Anecdotal reporting suggests TB-500 has a higher systemic travel capability, making it effective for injuries distal to the injection site.

03.

Safety & Regulatory Status

WADA / USADA Notice

As of January 1, 2022, Thymosin Beta-4 and its derivatives (including TB-500) are explicitly listed as prohibited substances in all competitive sports under the S2 Peptide Hormones and Growth Factors category.

Banned In-Competition Banned Out-of-Competition

Reported Risks

  • • Pro-angiogenic (Potential tumor growth risk)
  • • Lethargy post-administration
  • • Site irritation
  • • Long-term human safety data: Incomplete
04.

Evidence Matrix

Condition Studied Evidence Level Primary Outcome Reference
Myocardial Infarction Human Ph II Reduced scar tissue, improved LVEF NCT01140321
Epidermal Healing Human Ph III Accelerated wound closure in stasis ulcers RegeneRx 2018
Tendon Rupture Animal Model Increased tensile strength & collagen fiber alignment PMID: 256123..
Pillar Guide Ingredients Research Safety